logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9265767 B1

PDFFull Text
Date of Patent:
Feb. 23, 2016

Filed:

Oct. 31, 2014

1,2-disubstituted heterocyclic compounds

Applicant:

Forum Pharmaceuticals Inc., Watertown, MA (US);

Inventors:

Richard Chesworth, Concord, MA (US);

Amy Ripka, Reading, MA (US);

Gideon Shapiro, Gainesville, FL (US);

Assignee:

FORUM PHARMACEUTICALS INC., Waltham, MA (US);

Attorney:

Wilmer Hale Cutler Pickering and Dorr LLP

Primary Examiner:

Kristin Vajda

Int. Cl.
CPC ...
C07D 405/04 (2006.01); C07D 405/14 (2006.01); A61K 31/53 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 405/12 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); A61K 31/4375 (2006.01); A61K 31/4439 (2006.01); A61K 31/4709 (2006.01); A61K 31/498 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); C07D 403/14 (2006.01); C07D 471/04 (2006.01);
U.S. Cl.
CPC ...
A61K 31/53 (2013.01); A61K 31/4375 (2013.01); A61K 31/4439 (2013.01); A61K 31/4709 (2013.01); A61K 31/498 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/14 (2013.01); C07D 405/04 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01);
Abstract

1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not to, those associated with cognitive deficits or schizophrenic symptoms.

Find Patent Forward Citations

Loading…